Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
69 Cards in this Set
- Front
- Back
|
Abciximab (ReoPro) Indication
|
Adjunct to coronary intervention
|
|
|
Abciximab (ReoPro) Target
|
Platelet glycoprotein IIb/IIIa receptor
|
|
|
Abciximab (ReoPro) ADRs
|
Bleeding risk and thrombocytopenia
|
|
|
Alemtuzumab (Campath-1H) Indication
|
Cancer: B-CLL
|
|
|
Alemtuzumab (Campath-1H) Target
|
CD52 antigen
|
|
|
Alemtuzumab (Campath-1H) ADRs
|
hematologic toxicities
|
|
|
Obinutuzumab (Gazyva) Indication
|
Cancer: B-CLL
|
|
|
Obinutuzumab (Gazyva) Target
|
CD20 antigen
|
|
|
Obinutuzumab (Gazyva) ADRs
|
PML
hepatitis B virus reactivation |
|
|
Rituximab (Rituxan) Indication
|
Cancer: NHL
Rheumatoid Arthritis |
|
|
Rituximab (Rituxan) Target
|
CD20 Antigen
|
|
|
Rituximab (Rituxan) ADRs
|
PML
Hepatitis B reactivation Severe infusion reactions Tumor Lysis Syndrome Severe mucocutaneous reactions (SJS, TEN) |
|
|
Ibritumomab tiuxetin (Zevulin) Indication
|
Cancer: NHL
|
|
|
Ibritumomab tiuxetin (Zevulin) Target
|
CD 20 antigen
|
|
|
Ibritumomab tiuxetin (Zevulin) ADRs
|
Cytopenias
Mucocutaneous Reactions (given with rituximab in combo) |
|
|
Tositumomab (Bexxar) Indication
|
Cancer: NHL
|
|
|
Tositumomab (Bexxar) Target
|
CD20 antigen
|
|
|
Tositumomab (Bexxar) ADRs
|
cytopenias
|
|
|
Trastuzumab (Herceptin) Indication
|
Breast Cancer
Metastatic Gastric cancers |
|
|
Trastuzumab (Herceptin) Target
|
HER-2/neu
|
|
|
Trastuzumab (Herceptin) ADRs
|
cardiomyopathy
|
|
|
Ado-trastuzumab emtansine (Kadcyla) indications
|
Metastatic Breast Cancer
|
|
|
Ado-trastuzumab emtansine (Kadcyla) Target
|
HER-2
|
|
|
Ado-trastuzumab emtansine (Kadcyla) ADRs
|
Hepatotoxicity
Cardiac Toxicity Embryo-fetal toxicity |
|
|
Pertuzumab (Perjeta) Indication
|
Breast Cancer
|
|
|
Pertuzumab (Perjeta) Target
|
HER2
|
|
|
Pertuzumab (Perjeta) ADRs
|
Embry-fetal toxicity
Left ventricular dysfunction |
|
|
Cetuximab (Erbitux) Indication
|
Colorectal cancer
|
|
|
Cetuximab (Erbitux) Target
|
EGFR
|
|
|
Bevacizumab (Avastin) Indication
|
Colorectal Cancer
Breast Cancer |
|
|
Bevacizumab (Avastin) Target
|
VEGF
|
|
|
Bevacizumab (Avastin) ADRs
|
Wound healing complications
Hemorrhage |
|
|
Panitumomab (Vectibix) Indication
|
Colorectal Cancer
|
|
|
Panitumomab (Vectibix)Target
|
EGFR
**Patient must have wild-type KRAS status** |
|
|
Panitumomab (Vectibix) ADRs
|
Dermatologic toxicities including sepsis and septic death
|
|
|
Ziv-aflibercept (Zaltrap) Indication
|
Colorectal Cancer
|
|
|
Ziv-aflibercept (Zaltrap) Target
|
VEGF-A
VEGF-B PGIF |
|
|
Ziv-aflibercept (Zaltrap) ADRs
|
Hemorrhage
GI perforation Compromised wound healing Fertility impairment |
|
|
Ipilimumab (Yervoy) Indication
|
melanoma
|
|
|
Ipilimumab (Yervoy) Target
|
CTLA-4
|
|
|
Brentuximab vedotin (Adcetris) Indication
|
Hodgkin lymphoma
|
|
|
Brentuximab vedotin (Adcetris) Target
|
CD30
|
|
|
Brentuximab vedotin (Adcetris) ADRs
|
PML
|
|
|
Palivizumab (Synagis) indication
|
RSV
|
|
|
Palivizumab (Synagis) Target
|
F glycoprotein receptor
|
|
|
Omalizumab (Xolair) Indication
|
Asthma
|
|
|
Omalizumab (Xolair) Target
|
Human IgE
|
|
|
Omalizumab (Xolair) ADRs
|
anaphylaxis
|
|
|
Ranibizumab (Lucentis) Indication
|
Macular Degeneration
|
|
|
Ranibizumab (Lucentis) Target
|
VEGF
|
|
|
Ranibizumab (Lucentis) ADRs
|
Eye Infections
Increased pressure and optic nerve performation |
|
|
Aflibercept ( Eylea) Indication
|
Macular Degeneration
|
|
|
Aflibercept (Eylea) Target
|
VEGF-A
PIGF |
|
|
Aflibercept (Eylea) ADRs
|
Increased intraocular pressure
Impaired fertility |
|
|
Eculizumab (Soliris) Indication
|
Paroxyxmal nocturnal hemoglobinuria
|
|
|
Eculizumab (Soliris) Target
|
Complement protein C5
|
|
|
Eculizumab (Soliris) ADRs
|
Increased risk on meningococcal infections
|
|
|
Denosumab (Prolia;Xgeva) Indications
|
Osteoporosis
Bone Loss due to cancer Bone metastasis from solid tumors |
|
|
Denosumab (Prolia;Xgeva) Target
|
RANKL
|
|
|
2 drugs increase likelihood of patient on trastuzumab experiencing cardiomyopathy
|
1) Anthracycline
2) Cyclophosphamide |
|
|
Monoclonals with BBW for serious fungal infections
|
1) Remicade (Infliximab)
2) Enbrel (Etanercept) 3) Humira (Adalimumab) 4) Cimzia (Certolizumab pegol) 5) Simponi (Golimumab) 6) Actemra (tocilizumab) |
|
|
Monoclonals with PML warning
|
1) Tysabri (Natalizumab)
2) Rituximab (Rituxan) 3) Brentuximab vedotin 4) Infliximab 5) Obinutuzumab |
|
|
Monoclonals that are indicated for RA that act as TNF antagonist
|
1) Remicade (infliximab)
2) Enbrel (etanercept) 3) Humira (adalimumab) 4) Cimzia (certolizumab pegol) 5) Simponi (golimumab) |
|
|
Monoclonals that are indicated for RA that act at CD80 and CD86
|
Orencia (Abatacept)
|
|
|
Monoclonal indicated for RA that act at IL-6 antagonist
|
Actemra (tocilizumab)
|
|
|
Monoclonals with labeled indications for Crohn's Disease
|
1) Remicade (infliximab)
2) Cimzia (certolizumab pegol) 3) Humira (adalimumab) 4) Tysabri (natalizumab) |
|
|
Monoclonals indicated for psoriasis and/or psoriatic arthritis
|
1) Remicade (infliximab)
2) Enbrel (etanercept) 3) Humira (adalimumab) 4) Simponi (golimumab) 5) Stelara (ustekinumab) |
|
|
Monoclonals for Multiple Sclerosis
|
Tysabri (natalizumab)
|
|
|
Birdshot Chorioretinopathy
|
Rare, bilateral posterior uveitis of the eye
Leads to severe, progressive inflammation *floaters, macular edema, flashing lights in eyes, loss of color vision, complete loss of vision* |
